Logo
STELARA® in Inflammatory Bowel Disease

Real-world evidence confirms STELARA®’s efficacy seen in clinical trials

Comparative cohort
ENEIDA registry
sustAIN study

In a recent Dutch registry, STELARA® provides significantly higher effectiveness and lower discontinuation rates compared to vedolizumab at 52 weeks in CD patients with prior anti-TNF failure[4]

UNADJUSTED PROPORTION OF PATIENTS ACHIEVING CORTICOSTEROID-FREE CLINICAL REMISSION (HBI ≤4) WITH STELARA® COMPARED TO VEDOLIZUMAB*[4]
unadjusted proportion of patients achieving corticosteroid-free clinical remission with STELARA compared to vedolizumab
UNADJUSTED CUMULATIVE DRUG SURVIVAL OF VEDOLIZUMAB- AND STELARA®-TREATED PATIENTS*[4]
unadjusted cumulative drug survival of vedolizumab- and STELARA-treated patients

*1 patient received Q4W and 1 patient received Q6W dosing.

In the RUN-CD real-world study, STELARA® shows higher rates of clinical remission at Week 16 in comparison to other biologics†[5][6]

PROPORTION OF PATIENTS ACHIEVING CLINICAL REMISSION WITH STELARA® VS OTHER BIOLOGICS AT WEEK 16[5][6]
proportion of patients achieving clinical remission with STELARA vs other biologics at week 16

In the RUN-CD real-world study, STELARA® shows higher rates of health-related QoL improvements at Week 16 in comparison to other biologics‡[5]

EQ-5D VAS DIFFERENCE BETWEEN BASELINE AND WEEK 16
(INDUCTION PHASE)§[5]
EQ-5D VAS difference between baseline and week 16 (induction phase)

CD: Crohn’s disease; HBI: Harvey-Bradshaw Index; q8w: Every 8 weeks; SC: Subcutaneous; TNF: Tumour necrosis factor.

Clinical remission (HBI ≤4), and steroid-free remission (HBI ≤4 and no systemic use of steroids or budesonide during the last 8 weeks).
Other biologics included adalimumab (50.3%), infliximab (37.4%) and vedolizumab (12.3%).
§ Includes mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

References

Agrawal M, et al. Gastroenterology. 2021; 161(1): 47-65.
Berg DR, et al. Inflamm Bowel Dis. 2019; 25(12): 1896-1905.
Loy L, et al. Expert Rev Gastroenterol Hepatol. 2019; 13(6): 547-555.
Biemans VBC, et al. Aliment Pharmacol Ther. 2020; 52: 123-134.
Bokemeyer B, et al. Abstract 526 presented at Digestive Disease Week (DDW) 21–23 May 2021. Virtual event.
Bokemeyer B, et al. DOP47 presented at European Crohn’s and Colitis Organisation (ECCO) 15thCongress, 12–15 February 2020, Vienna, Austria.
Iborra M, et al. Aliment Pharmacol Ther. 2019; 50: 278-288.
Iborra M, et al. Aliment Pharmacol Ther. 2020; 50: 1017-1030.
Chaparro M, et al. Poster presentation P0506 presented at the United European Gastroenterology Week (UEGW), 11-13 October 2020, virtual event.
Chaparro M, et al. Poster presentation P0507 presented at the United European Gastroenterology Week (UEGW), 11-13 October 2020, virtual event.
Chaparro M, et al. Poster presentation P263 presented at the European Crohn’s and Colitis Organisation (ECCO), 2-3 & 10-11 July 2021, virtual event.
CP-246633 - January 2021